Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis
ConclusionsOCA + losartan suppressed the ongoing hepatic fibrosis by attenuating gut barrier dysfunction and suppressing Ac-HSC proliferation. Combined therapy may be a promising novel approach for NASH with fibrosis.
Source: Indian Journal of Gastroenterology - Category: Gastroenterology Source Type: research
More News: Cozaar | Diets | Gastroenterology | India Health | Liver | Losartan | Nutrition | Urology & Nephrology